Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis

Makoto Okuya, Shinji Matsunaga, Toshikazu Ikuta, Taro Kishi, Nakao Iwata

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n=801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference=2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD.

Original languageEnglish
Pages (from-to)1379-1387
Number of pages9
JournalJournal of Alzheimer's Disease
Volume66
Issue number4
DOIs
Publication statusPublished - 01-01-2018

Fingerprint

Intravenous Immunoglobulins
Intravenous Administration
Meta-Analysis
Alzheimer Disease
Safety
Placebos
Behavioral Symptoms
Exanthema
Cognition
Dementia
Psychology
Incidence

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{627a1b6bcdb14c5d8b4ab7d413c418f1,
title = "Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis",
abstract = "A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n=801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference=2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD.",
author = "Makoto Okuya and Shinji Matsunaga and Toshikazu Ikuta and Taro Kishi and Nakao Iwata",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/JAD-180888",
language = "English",
volume = "66",
pages = "1379--1387",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease : A Systematic Review and Meta-Analysis. / Okuya, Makoto; Matsunaga, Shinji; Ikuta, Toshikazu; Kishi, Taro; Iwata, Nakao.

In: Journal of Alzheimer's Disease, Vol. 66, No. 4, 01.01.2018, p. 1379-1387.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease

T2 - A Systematic Review and Meta-Analysis

AU - Okuya, Makoto

AU - Matsunaga, Shinji

AU - Ikuta, Toshikazu

AU - Kishi, Taro

AU - Iwata, Nakao

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n=801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference=2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD.

AB - A systematic review and meta-analysis of the efficacy/safety of intravenous immunoglobulin (IVIG) administration in mild-to-moderate Alzheimer's disease (AD) patients was performed. Six randomized double-blind, placebo-controlled trials (n=801) were included in this study. No significant difference in cognitive function was observed between the groups. Moreover, IVIG was inferior to placebo in behavioral disturbances (mean difference=2.19). Further, IVIG administration was associated with a higher incidence of rash than placebo. Our results do not support IVIG administration for mild-to-moderate AD, suggesting that IVIG is not effective to treat mild-to-moderate AD and that it deteriorates behavioral and psychological symptoms of dementia in mild-to-moderate AD.

UR - http://www.scopus.com/inward/record.url?scp=85058781976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058781976&partnerID=8YFLogxK

U2 - 10.3233/JAD-180888

DO - 10.3233/JAD-180888

M3 - Article

C2 - 30452419

AN - SCOPUS:85058781976

VL - 66

SP - 1379

EP - 1387

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -